title: Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma.
authors.affiliation: Westmead Hospital, Sydney, New South Wales, Australia.
authors.forename: Oliver
authors.initials: O
authors.lastname: Klein
authors.forename: Antoni
authors.initials: A
authors.lastname: Ribas
authors.forename: Bartosz
authors.initials: B
authors.lastname: Chmielowski
authors.forename: Grant
authors.initials: G
authors.lastname: Walker
authors.forename: Arthur
authors.initials: A
authors.lastname: Clements
authors.forename: Georgina V
authors.initials: GV
authors.lastname: Long
authors.forename: Richard F
authors.initials: RF
authors.lastname: Kefford
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D005158:Facial Paralysis / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D008297:Male; D008545:Melanoma / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use*; D013449:Sulfonamides / Q000009:adverse effects*; D016896:Treatment Outcome; D000077484:Vemurafenib
chemical_list: D018931:Antineoplastic Agents, Hormonal; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; D011241:Prednisone